Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLYER: 4 vs 6 Cycles of R-CHOP in Young Low-Risk Aggressive B-Cell Lymphoma
NCT00278421Phase 3Completed
- Sponsor
- German High-Grade Non-Hodgkin Lymphoma Study Group
- Start
- Nov 2005
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in B-cell non-Hodgkin lymphoma (2 arms), sponsored by German High-Grade Non-Hodgkin Lymphoma Study Group. Primary endpoint: Time to Treatment Failure at 3 years. Started Nov 2005; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00278421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278421.